Intelligence Β· Clinical Pipeline
Phase I Pipeline Programs
First-in-human and early clinical safety studies in Phase I.
- Programs
- 4,713
Quick answer
NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 327 programs
- Takeda 276 programs
- Anaxis Pharma 204 programs
- Chinese Academy of 190 programs
- United Therapeutics Europe 184 programs
- Teva Pharma 154 programs
- First People's Hospital 149 programs
- Regeneron UK 126 programs
- Boehringer Ingelheim 94 programs
- Sunshine Guojian Pharmaceutical 85 programs
- Lakefront Biotherapeutics NV 62 programs
- HOFFMANN-LA ROCHE 58 programs
-
TAF/EVG vaginal insert
United Therapeutics Europe Ltd
Safety Issues
1 trial -
TAK-004
Takeda
Healthy Volunteers
1 trial -
TAK-007
Takeda
Refractory Lupus Nephritis
1 trial -
TAK-020
Takeda
Healthy Volunteers
1 trial -
TAK-020 Captisol Oral Solution
Takeda
Healthy
1 trial -
TAK-041
NEUROCRINE BIOSCIENCES INC
Healthy Volunteers
1 trial -
TAK-058
Takeda
Schizophrenia
1 trial -
TAK-058
Takeda
Healthy Volunteers
1 trial -
TAK-058 (ENV8058)
Takeda
Dose Finding Study
1 trial -
TAK-063
Takeda
Schizophrenia
1 trial -
TAK-063
Takeda
Healthy Volunteers
1 trial -
TAK-071
Takeda
Alzheimer Disease
1 trial -
TAK-079
Takeda
Systemic Lupus Erythematosus
1 trial -
TAK-079
Takeda
Multiple Myeloma
1 trial -
TAK-079
Takeda
Autoimmune Disease
1 trial -
TAK-102
Takeda
Solid Tumors
1 trial -
TAK-103
Takeda
Solid Tumors
1 trial -
TAK-105-a
Takeda
Healthy Volunteers
1 trial -
TAK-114 10 mg capsule
Takeda
Clinical Pharmacology
1 trial -
TAK-117
Takeda
Neoplasm, Advanced or Metastatic
1 trial -
TAK-117
Takeda
Metastatic Solid Tumors
1 trial -
TAK-123
Takeda
Healthy Volunteers
1 trial -
TAK-137
Takeda
Dose Finding Study
1 trial -
TAK-137
Takeda
Attention-Deficit/Hyperactivity Disorder
1 trial -
TAK-137 5 mg tablet, TAK-137 placebo tablet
Takeda
Healthy Japanese Adult Male
1 trial -
TAK-164
Takeda
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
1 trial -
TAK-165
Takeda
Breast Neoplasm
1 trial -
TAK-227
Takeda
Healthy Volunteers
1 trial -
TAK-228
Takeda
Advanced Nonhematologic Malignancies
1 trial -
TAK-233
Takeda
Clinical Pharmacology
1 trial -
TAK-272
Takeda
Renal Impairment
1 trial -
TAK-272
Takeda
Japanese Healthy Adult Males
1 trial -
TAK-279
Takeda
Renal Impairment
1 trial -
TAK-279
Takeda
Hepatic Impairment
1 trial -
TAK-279
Takeda
Healthy Volunteers
3 trials -
TAK-329
Takeda
Type 1 Diabetes Mellitus
1 trial -
TAK-385
Takeda
Hormone Treatment-naΓ―ve Participants With Prostate Cancer
1 trial -
TAK-385 40 mg
Takeda
Japanese Premenopausal Healthy Adult Women
1 trial -
TAK-385 T2 Formulation
Takeda
Healthy Volunteers
1 trial -
TAK-418
Takeda
Healthy Volunteers
2 trials -
TAK-418
Takeda
Healthy Participants
1 trial -
TAK-438
Takeda
Dose Finding Study
2 trials -
TAK-438
Takeda
Ascending Single Dose Study
1 trial -
TAK-438
Takeda
Healthy Volunteers
1 trial -
TAK-438
Takeda
Healthy Participants
1 trial -
TAK-438
Takeda
Erosive Esophagitis(EE)
1 trial -
TAK-438 OD
Takeda
Japanese Healthy Adult Male
1 trial -
TAK-438ASA
Takeda
Healthy Volunteers
1 trial
Frequently asked questions
How many Phase I pipeline programs are in the directory?
4,713 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources Β· All pipeline programs